Using PAMPs and DAMPs as adjuvants in cancer vaccines

References

• Wang JJ, Lei KF, Han F. Tumor microenvironment: recent advances in various cancer treatments. Eur Rev Med Pharmacol Sci. 2018;22:3855–64.
   PubMed Web of Science ®Google Scholar
• Garcon N, Chomez P, Van Mechelen M. GlaxoSmithKline adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines. 2007;6:723–39. doi:10.1586/14760584.6.5.723.
   PubMed Web of Science ®Google Scholar
• Golos A, Lutynska A. Aluminium-adjuvanted vaccines–a review of the current state of knowledge. Przegl Epidemiol. 2015;69:871–74.
   Google Scholar
• Gatti-Mays ME, Redman JM, Collins JM, Bilusic M. Cancer vaccines: enhanced immunogenic modulation through therapeutic combinations. Hum Vaccin Immunother. 2017;13:2561–74. doi:10.1080/21645515.2017.1364322.
   PubMed Web of Science ®Google Scholar
• Aldous AR, Dong JZ. Personalized neoantigen vaccines: a new approach to cancer immunotherapy. Bioorg Med Chem. 2018;26:2842–49. doi:10.1016/j.bmc.2017.10.021.
   PubMed Web of Science ®Google Scholar
• Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, Farsaci B, Madan RA, Heery CR, Gulley JL. Therapeutic cancer vaccines. Adv Cancer Res. 2014;121:67–124.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–52. doi:10.1038/32588.
   PubMed Web of Science ®Google Scholar
• DeMaria PJ, Cancer Vaccines BM. Cancer vaccines. Hematol Oncol Clin North Am. 2019;33(2):199–214. doi:10.1016/j.hoc.2018.12.001.
   PubMed Web of Science ®Google Scholar
• Handy CE, Antonarakis ES. Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions. Future Oncol. 2018;14:907–17. doi:10.2217/fon-2017-0531.
   PubMed Web of Science ®Google Scholar
• Burke EE, Kodumudi K, Ramamoorthi G, Czerniecki BJ. Vaccine therapies for Breast Cancer. Surg Oncol Clin N Am. 2019;28:353–67. doi:10.1016/j.soc.2019.02.004.
   PubMed Web of Science ®Google Scholar
• Tiptiri-Kourpeti A, Spyridopoulou K, Pappa A, Chlichlia K. DNA vaccines to attack cancer: strategies for improving immunogenicity and efficacy. Pharmacol Ther. 2016;165:32–49.
   PubMed Web of Science ®Google Scholar
• Pilla L, Ferrone S, Maccalli C. Methods for improving the immunogenicity and efficacy of cancer vaccines. Expert Opin Biol Ther. 2018;18:765–84. doi:10.1080/14712598.2018.1485649.
   PubMed Web of Science ®Google Scholar
• Banerjee K, Kumar S, Ross KA, Gautam S, Poelaert B, Nasser MW, Aithal A, Bhatia R, Wannemuehler MJ, Narasimhan B, et al. Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett. 2018;417:35–46. doi:10.1016/j.canlet.2017.12.012.
   PubMed Web of Science ®Google Scholar
• Wagner S, Mullins CS, Linnebacher M. Colorectal cancer vaccines: tumor-associated antigens vs neoantigens. World J Gastroenterol. 2018;24:5418–32. doi:10.3748/wjg.v24.i48.5418.
   PubMed Web of Science ®Google Scholar
• Tran T, Blanc C, Granier C, Saldmann A, Tanchot C, Tartour E. Therapeutic cancer vaccine: building the future from lessons of the past. Semin Immunopathol. 2019;41:69–85. doi:10.1007/s00281-018-0691-z.
   PubMed Web of Science ®Google Scholar
• Peng M, Mo Y, Wang Y, Wu P, Zhang Y, Xiong F, Guo C, Wu X, Li Y, Li X, et al. Neoantigen vaccine: an emerging tumor immunotherapy. Mol Cancer. 2019;18:128. doi:10.1186/s12943-019-1055-6.
   PubMed Web of Science ®Google Scholar
• Veisi Malekshahi Z, Hashemi Goradel N, Shakouri Khomartash M, Maleksabet A, Kadkhodazadeh M, Kardar GA, Negahdari B. CEA plasmid as therapeutic DNA vaccination against colorectal Cancer. Iran J Immunol. 2019;16:235–45.
   PubMed Web of Science ®Google Scholar
• Li YL, Qiu XH, Shen C, Liu JN, Zhang J. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors. Oncol Rep. 2010;24:1323–29.
   PubMed Web of Science ®Google Scholar
• Martinez-Perez AG, Perez-Trujillo JJ, Garza-Morales R, Ramirez-Avila NE, Loera-Arias MJ, Gomez-Gutierrez JG, Saucedo-Cardenas O, Garcia-Garcia A, Rodriguez-Rocha H, Montes-de-Oca-Luna R, et al. An oncolytic adenovirus encoding SA-4-1BBL adjuvant fused to HPV-16 E7 antigen produces a specific antitumor effect in a Cancer Mouse model. Vaccines (Basel). 2021;9:149. doi:10.3390/vaccines9020149.
   PubMed Web of Science ®Google Scholar
• Garza-Morales R, Perez-Trujillo JJ, Martinez-Jaramillo E, Saucedo-Cardenas O, Loera-Arias MJ, Garcia-Garcia A, Rodriguez-Rocha H, Yolcu E, Shirwan H, Gomez-Gutierrez J, et al. A DNA vaccine encoding SA-4-1BBL fused to HPV-16 E7 antigen has prophylactic and therapeutic efficacy in a cervical Cancer Mouse model. Cancers (Basel). 2019;11:96. doi:10.3390/cancers11010096.
   PubMed Web of Science ®Google Scholar
• Gautam SK, Kumar S, Dam V, Ghersi D, Jain M, Batra SK. MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy. Semin Immunol. 2020;47:101391. doi:10.1016/j.smim.2020.101391.
   PubMed Web of Science ®Google Scholar
• Pan RY, Chung WH, Chu MT, Chen SJ, Chen HC, Zheng L, Hung S-I. Recent development and clinical application of cancer vaccine: targeting neoantigens. J Immunol Res. 2018;2018:4325874. doi:10.1155/2018/4325874.
   PubMed Web of Science ®Google Scholar
• Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol. 2016;28:329–38. doi:10.1093/intimm/dxw015.
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Clementi E, Radice S. On vaccine’s adjuvants and autoimmunity: current evidence and future perspectives. Autoimmun Rev. 2015;14:880–88. doi:10.1016/j.autrev.2015.05.014.
   PubMed Web of Science ®Google Scholar
• Shah RR, Hassett KJ, Brito LA. Overview of vaccine adjuvants: introduction, history, and current status. Methods Mol Biol. 2017;1494:1–13.
   PubMedGoogle Scholar
• Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol. 1989;54(Pt 1):1–13. doi:10.1101/SQB.1989.054.01.003.
   PubMedGoogle Scholar
• Satoh T, Akira S, Gordon S. Toll-Like Receptor Signaling and Its Inducible Proteins. Microbiol Spectr. 2016;4:1–7. doi:10.1128/microbiolspec.MCHD-0040-2016.
   Web of Science ®Google Scholar
• Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003;85:85–95. doi:10.1016/S0165-2478(02)00228-6.
   PubMed Web of Science ®Google Scholar
• Tang D, Kang R, Coyne CB, Zeh HJ, Lotze MT. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev. 2012;249:158–75. doi:10.1111/j.1600-065X.2012.01146.x.
   PubMed Web of Science ®Google Scholar
• Delgado MA, Elmaoued RA, Davis AS, Kyei G, Deretic V. Toll-like receptors control autophagy. EMBO J. 2008;27:1110–21. doi:10.1038/emboj.2008.31.
   PubMed Web of Science ®Google Scholar
• Cui J, Chen Y, Wang HY, Wang RF. Mechanisms and pathways of innate immune activation and regulation in health and cancer. Hum Vaccin Immunother. 2014;10:3270–85. doi:10.4161/21645515.2014.979640.
   PubMed Web of Science ®Google Scholar
• Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994;12:991–1045. doi:10.1146/annurev.iy.12.040194.005015.
   PubMed Web of Science ®Google Scholar
• Land W, Schneeberger H, Schleibner S, Illner WD, Abendroth D, Rutili G, Arfors KE, Messmer K. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation. 1994;57:211–17. doi:10.1097/00007890-199401001-00010.
   PubMed Web of Science ®Google Scholar
• Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516–21. doi:10.1038/nature01991.
   PubMed Web of Science ®Google Scholar
• Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191–95. doi:10.1038/nature00858.
   PubMed Web of Science ®Google Scholar
• Fleshner M, Crane CR. Exosomes, DAMPs and miRNA: features of stress physiology and immune homeostasis. Trends Immunol. 2017;38:768–76. doi:10.1016/j.it.2017.08.002.
   PubMed Web of Science ®Google Scholar
• Patel S. Danger-Associated Molecular Patterns (DAMPs): the derivatives and triggers of inflammation. Curr Allergy Asthma Rep. 2018;18:63. doi:10.1007/s11882-018-0817-3.
   PubMed Web of Science ®Google Scholar
• Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao L, Huang J, Yu Y, Fan XG, Yan Z, et al. HMGB1 in health and disease. Mol Aspects Med. 2014;40:1–116.
   PubMed Web of Science ®Google Scholar
• Garg AD, Dudek AM, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors. 2013;39:355–67. doi:10.1002/biof.1125.
   PubMed Web of Science ®Google Scholar
• Raghavan M, Wijeyesakere SJ, Peters LR, Del Cid N. Calreticulin in the immune system: ins and outs. Trends Immunol. 2013;34:13–21. doi:10.1016/j.it.2012.08.002.
   PubMed Web of Science ®Google Scholar
• Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ, Geczy CL. Functions of S100 proteins. Curr Mol Med. 2013;13:24–57. doi:10.2174/156652413804486214.
   PubMed Web of Science ®Google Scholar
• Nace G, Evankovich J, Eid R, Tsung A. Dendritic cells and damage-associated molecular patterns: endogenous danger signals linking innate and adaptive immunity. J Innate Immun. 2012;4:6–15. doi:10.1159/000334245.
   PubMed Web of Science ®Google Scholar
• Wilgus TA. Alerting the body to tissue injury: the role of alarmins and DAMPs in cutaneous wound healing. Curr Pathobiol Rep. 2018;6:55–60. doi:10.1007/s40139-018-0162-1.
   PubMedGoogle Scholar
• Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol. 2007;81:1–5.
   PubMed Web of Science ®Google Scholar
• Idzko M, Ferrari D, Eltzschig HK. Nucleotide signalling during inflammation. Nature. 2014;509:310–17. doi:10.1038/nature13085.
   PubMed Web of Science ®Google Scholar
• Venereau E, Ceriotti C, Bianchi ME. DAMPs from cell death to new life. Front Immunol. 2015;6:422. doi:10.3389/fimmu.2015.00422.
   PubMed Web of Science ®Google Scholar
• Krentz T, Allen S. Bacterial translocation in critical illness. J Small Anim Pract. 2017;58:191–98. doi:10.1111/jsap.12626.
   PubMed Web of Science ®Google Scholar
• Zindel J, Kubes P. DAMPs, PAMPs, and LAMPs in immunity and sterile inflammation. Annu Rev Pathol. 2020;15:493–518. doi:10.1146/annurev-pathmechdis-012419-032847.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–75. doi:10.1038/nrc3380.
   PubMed Web of Science ®Google Scholar
• Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, et al. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med. 2012;209:551–63. doi:10.1084/jem.20111739.
   PubMed Web of Science ®Google Scholar
• Ellson CD, Dunmore R, Hogaboam CM, Sleeman MA, Murray LA. Danger-associated molecular patterns and danger signals in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2014;51:163–68.
   PubMed Web of Science ®Google Scholar
• Mandke P, Vasquez KM. Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: implications in DNA repair and immune responses. DNA Repair (Amst). 2019;83:102701. doi:10.1016/j.dnarep.2019.102701.
   PubMed Web of Science ®Google Scholar
• Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012;8:195–202. doi:10.1038/nrrheum.2011.222.
   PubMed Web of Science ®Google Scholar
• Yang Q, Shi Y, Yang Y, Lou G, Chen Z. The sterile inflammation in the exacerbation of HBV-associated liver injury. Mediators Inflamm. 2015;2015:508681. doi:10.1155/2015/508681.
   PubMed Web of Science ®Google Scholar
• Oczypok EA, Perkins TN, Oury TD. All the “RAGE” in lung disease: the receptor for advanced glycation endproducts (RAGE) is a major mediator of pulmonary inflammatory responses. Paediatr Respir Rev. 2017;23:40–49.
   PubMed Web of Science ®Google Scholar
• Kierdorf K, Fritz G. RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol. 2013;94:55–68. doi:10.1189/jlb.1012519.
   PubMed Web of Science ®Google Scholar
• Tian J, Avalos AM, Mao SY, Chen B, Senthil K, Wu H, Parroche P, Drabic S, Golenbock D, Sirois C, et al. Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 2007;8:487–96. doi:10.1038/ni1457.
   PubMed Web of Science ®Google Scholar
• Wang X, Sun R, Wei H, Tian Z. High-mobility group box 1 (HMGB1)-Toll-like receptor (TLR)4-interleukin (IL)-23-IL-17A axis in drug-induced damage-associated lethal hepatitis: interaction of gammadelta T cells with macrophages. Hepatology. 2013;57:373–84. doi:10.1002/hep.25982.
   PubMed Web of Science ®Google Scholar
• Szeto V, Chen NH, Sun HS, Feng ZP. The role of KATP channels in cerebral ischemic stroke and diabetes. Acta Pharmacol Sin. 2018;39:683–94. doi:10.1038/aps.2018.10.
   PubMed Web of Science ®Google Scholar
• Kouzaki H, Iijima K, Kobayashi T, O’Grady SM, Kita H. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol. 2011;186:4375–87. doi:10.4049/jimmunol.1003020.
   PubMed Web of Science ®Google Scholar
• Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11:201–12. doi:10.1038/nri2938.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C, Vermaelen K, Panaretakis T, Mignot G, Ullrich E, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15:1170–78. doi:10.1038/nm.2028.
   PubMed Web of Science ®Google Scholar
• Cui B, Liu X, Fang Y, Zhou P, Zhang Y, Wang Y. Flagellin as a vaccine adjuvant. Expert Rev Vaccines. 2018;17:335–49. doi:10.1080/14760584.2018.1457443.
   PubMed Web of Science ®Google Scholar
• Kawai T, Akira S. TLR signaling. Semin Immunol. 2007;19:24–32. doi:10.1016/j.smim.2006.12.004.
   PubMed Web of Science ®Google Scholar
• Smith KD, Andersen-Nissen E, Hayashi F, Strobe K, Bergman MA, Barrett SL, Cookson BT, Aderem A. Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility. Nat Immunol. 2003;4:1247–53. doi:10.1038/ni1011.
   PubMed Web of Science ®Google Scholar
• Miao EA, Andersen-Nissen E, Warren SE, Aderem A. TLR5 and Ipaf: dual sensors of bacterial flagellin in the innate immune system. Semin Immunopathol. 2007;29:275–88. doi:10.1007/s00281-007-0078-z.
   PubMed Web of Science ®Google Scholar
• Miao EA, Alpuche-Aranda CM, Dors M, Clark AE, Bader MW, Miller SI, et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1beta via Ipaf. Nat Immunol. 2006;7:569–75.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature. 2004;430:213–18. doi:10.1038/nature02664.
   PubMed Web of Science ®Google Scholar
• Lightfield KL, Persson J, Brubaker SW, Witte CE, von Moltke J, Dunipace EA, Henry T, Sun Y-H, Cado D, Dietrich WF, et al. Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat Immunol. 2008;9:1171–78. doi:10.1038/ni.1646.
   PubMed Web of Science ®Google Scholar
• Faham A, Altin JG. Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J Immunol. 2010;185:1744–54. doi:10.4049/jimmunol.1000027.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Momota M, Kuroda E, Kusakabe T, Kobari S, Makisaka K, Ohno Y, Suzuki Y, Nakagawa F, Lee MSJ, et al. DAMP-inducing adjuvant and PAMP adjuvants parallelly enhance protective Type-2 and Type-1 immune responses to influenza split vaccination. Front Immunol. 2018;9:2619. doi:10.3389/fimmu.2018.02619.
   PubMed Web of Science ®Google Scholar
• Panda AK. Induction of anti-tumor immunity and T-cell responses using nanodelivery systems engrafting TLR-5 ligand. Expert Rev Vaccines. 2011;10:155–57. doi:10.1586/erv.10.164.
   PubMed Web of Science ®Google Scholar
• Rossol M, Heine H, Meusch U, Quandt D, Klein C, Sweet MJ, Hauschildt S. LPS-induced cytokine production in human monocytes and macrophages. Crit Rev Immunol. 2011;31:379–446. doi:10.1615/CritRevImmunol.v31.i5.20.
   PubMed Web of Science ®Google Scholar
• Mochizuki S, Morishita H, Kobiyama K, Aoshi T, Ishii KJ, Sakurai K. Immunization with antigenic peptides complexed with beta-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs. J Control Release. 2015;220:495–502. doi:10.1016/j.jconrel.2015.11.008.
   PubMed Web of Science ®Google Scholar
• Jin JW, Tang SQ, Rong MZ, Zhang MQ. Synergistic effect of dual targeting vaccine adjuvant with aminated beta-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses. Acta Biomater. 2018;78:211–23. doi:10.1016/j.actbio.2018.08.002.
   PubMed Web of Science ®Google Scholar
• Doita M, Rasmussen LT, Seljelid R, Lipsky PE. Effect of soluble aminated beta-1,3-D-polyglucose on human monocytes: stimulation of cytokine and prostaglandin E2 production but not antigen-presenting function. J Leukoc Biol. 1991;49:342–51. doi:10.1002/jlb.49.4.342.
   PubMed Web of Science ®Google Scholar
• Tincer G, Yerlikaya S, Yagci FC, Kahraman T, Atanur OM, Erbatur O, Gursel I. Immunostimulatory activity of polysaccharide-poly(I:C) nanoparticles. Biomaterials. 2011;32:4275–82. doi:10.1016/j.biomaterials.2011.01.028.
   PubMed Web of Science ®Google Scholar
• Han J, Cai J, Borjihan W, Ganbold T, Rana TM, Baigude H. Preparation of novel curdlan nanoparticles for intracellular siRNA delivery. Carbohydr Polym. 2015;117:324–30. doi:10.1016/j.carbpol.2014.09.069.
   PubMed Web of Science ®Google Scholar
• Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines. 2010;9:1095–107. doi:10.1586/erv.10.89.
   PubMed Web of Science ®Google Scholar
• Li X, Sloat BR, Yanasarn N, Cui Z. Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. Eur J Pharm Biopharm. 2011;78:107–16. doi:10.1016/j.ejpb.2010.12.017.
   PubMed Web of Science ®Google Scholar
• Gutierro I, Hernandez RM, Igartua M, Gascon AR, Pedraz JL. Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. Vaccine. 2002;21:67–77. doi:10.1016/S0264-410X(02)00435-8.
   PubMed Web of Science ®Google Scholar
• Fifis T, Gamvrellis A, Crimeen-Irwin B, Pietersz GA, Li J, Mottram PL, McKenzie IFC, Plebanski M. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol. 2004;173:3148–54. doi:10.4049/jimmunol.173.5.3148.
   PubMed Web of Science ®Google Scholar
• Xiang SD, Scholzen A, Minigo G, David C, Apostolopoulos V, Mottram PL, Plebanski M. Pathogen recognition and development of particulate vaccines: does size matter? Methods. 2006;40:1–9. doi:10.1016/j.ymeth.2006.05.016.
   PubMed Web of Science ®Google Scholar
• Russell J, Mumper, Z, Cui, Moses, et al. Nanotemplate engineering of cell specific nanoparticles. Journal of Dispersion Science and Technology. 2003;24:569–88.
   Google Scholar
• Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res. 2003;20:212–20. doi:10.1023/A:1022219003551.
   PubMed Web of Science ®Google Scholar
• Miyake Y, Yamasaki S. Sensing necrotic cells. Adv Exp Med Biol. 2012;738:144–52.
   PubMed Web of Science ®Google Scholar
• Ciocca DR, Cayado-Gutierrez N, Maccioni M, Cuello-Carrion FD. Heat shock proteins (HSPs) based anti-cancer vaccines. Curr Mol Med. 2012;12:1183–97. doi:10.2174/156652412803306684.
   PubMed Web of Science ®Google Scholar
• Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367–88. doi:10.1146/annurev.immunol.021908.132603.
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31:51–72. doi:10.1146/annurev-immunol-032712-100008.
   PubMed Web of Science ®Google Scholar
• Fagone P, Shedlock DJ, Bao H, Kawalekar OU, Yan J, Gupta D, Morrow MP, Patel A, Kobinger GP, Muthumani K, et al. Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination. Gene Ther. 2011;18:1070–77. doi:10.1038/gt.2011.59.
   PubMed Web of Science ®Google Scholar
• Grover A, Troudt J, Foster C, Basaraba R, Izzo A. High mobility group box 1 acts as an adjuvant for tuberculosis subunit vaccines. Immunology. 2014;142:111–23. doi:10.1111/imm.12236.
   PubMed Web of Science ®Google Scholar
• Muthumani G, Laddy DJ, Sundaram SG, Fagone P, Shedlock DJ, Kannan S, Wu L, Chung CW, Lankaraman KM, Burns J, et al. Co-immunization with an optimized plasmid-encoded immune stimulatory interleukin, high-mobility group box 1 protein, results in enhanced interferon-gamma secretion by antigen-specific CD8 T cells. Immunology. 2009;128:e612–20. doi:10.1111/j.1365-2567.2009.03044.x.
   PubMed Web of Science ®Google Scholar
• Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Müller S, Iannacone M, Traversari C, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004;5:825–30. doi:10.1038/sj.embor.7400205.
   PubMed Web of Science ®Google Scholar
• Dhakal J, Brah GS, Agrawal RK, Pawar HN, Kaur D, Verma R. Over-expression of gene encoding heat shock protein 70 from Mycobacterium tuberculosis and its evaluation as vaccine adjuvant. Indian J Med Microbiol. 2013;31:123–29.
   PubMed Web of Science ®Google Scholar
• Brenner BG, Wainberg MA. Heat shock protein-based therapeutic strategies against human immunodeficiency virus type 1 infection. Infect Dis Obstet Gynecol. 1999;7:80–90.
   PubMedGoogle Scholar
• Pack CD, Kumaraguru U, Suvas S, Rouse BT. Heat-shock protein 70 acts as an effective adjuvant in neonatal mice and confers protection against challenge with herpes simplex virus. Vaccine. 2005;23:3526–34. doi:10.1016/j.vaccine.2005.01.152.
   PubMed Web of Science ®Google Scholar
• Wan T, Zhou X, Chen G, An H, Chen T, Zhang W, Liu S, Jiang Y, Yang F, Wu Y, et al. Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. Blood. 2004;103:1747–54. doi:10.1182/blood-2003-08-2828.
   PubMed Web of Science ®Google Scholar
• Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011;29:139–62. doi:10.1146/annurev-immunol-030409-101323.
   PubMed Web of Science ®Google Scholar
• Chandrashekaran V, Seth RK, Dattaroy D, Alhasson F, Ziolenka J, Carson J, Berger FG, Kalyanaraman B, Diehl AM, Chatterjee S, et al. HMGB1-RAGE pathway drives peroxynitrite signaling-induced IBD-like inflammation in murine nonalcoholic fatty liver disease. Redox Biol. 2017;13:8–19. doi:10.1016/j.redox.2017.05.005.
   PubMed Web of Science ®Google Scholar
• de Paulis A, Prevete N, Rossi FW, Rivellese F, Salerno F, Delfino G, Liccardo B, Avilla E, Montuori N, Mascolo M, et al. Helicobacter pylori Hp(2-20) promotes migration and proliferation of gastric epithelial cells by interacting with formyl peptide receptors in vitro and accelerates gastric mucosal healing in vivo. J Immunol. 2009;183:3761–69. doi:10.4049/jimmunol.0900863.
   PubMed Web of Science ®Google Scholar
• Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood. 2003;101:245–52. doi:10.1182/blood-2002-05-1580.
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97:889–901. doi:10.1016/S0092-8674(00)80801-6.
   PubMed Web of Science ®Google Scholar
• Holen I, Lefley DV, Francis SE, Rennicks S, Bradbury S, Coleman RE, Ottewell P. IL-1 drives breast cancer growth and bone metastasis in vivo. Oncotarget. 2016;7:75571–84. doi:10.18632/oncotarget.12289.
   PubMedGoogle Scholar
• Lee WL, Slutsky AS. Sepsis and endothelial permeability. N Engl J Med. 2010;363:689–91. doi:10.1056/NEJMcibr1007320.
   PubMed Web of Science ®Google Scholar
• Lu M, Ge Q, Wang G, Luo Y, Wang X, Jiang W, Liu X, Wu C-L, Xiao Y, Wang X, et al. CIRBP is a novel oncogene in human bladder cancer inducing expression of HIF-1alpha. Cell Death Dis. 2018;9:1046. doi:10.1038/s41419-018-1109-5.
   PubMed Web of Science ®Google Scholar
• Qiang X, Yang WL, Wu R, Zhou M, Jacob A, Dong W, Kuncewitch M, Ji Y, Yang H, Wang H, et al. Cold-inducible RNA-binding protein (CIRP) triggers inflammatory responses in hemorrhagic shock and sepsis. Nat Med. 2013;19:1489–95. doi:10.1038/nm.3368.
   PubMed Web of Science ®Google Scholar
• Tesar BM, Jiang D, Liang J, Palmer SM, Noble PW, Goldstein DR. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant. 2006;6:2622–35. doi:10.1111/j.1600-6143.2006.01537.x.
   PubMed Web of Science ®Google Scholar
• Venereau E, De Leo F, Mezzapelle R, Careccia G, Musco G, Bianchi ME. HMGB1 as biomarker and drug target. Pharmacol Res. 2016;111:534–44. doi:10.1016/j.phrs.2016.06.031.
   PubMed Web of Science ®Google Scholar
• Wei Y, Chen X, Liang C, Ling Y, Yang X, Ye X, Zhang H, Yang P, Cui X, Ren Y, et al. A noncoding regulatory RNAs network driven by Circ-CDYL acts specifically in the early stages hepatocellular carcinoma. Hepatology. 2020;71:130–47. doi:10.1002/hep.30795.
   PubMed Web of Science ®Google Scholar
• West AP, Khoury-Hanold W, Staron M, Tal MC, Pineda CM, Lang SM, Bestwick M, Duguay BA, Raimundo N, MacDuff DA, et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553–57. doi:10.1038/nature14156.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol. 2011;187:2626–31. doi:10.4049/jimmunol.1003930.
   PubMed Web of Science ®Google Scholar
• Yan X, Chen S, Huang H, Peng T, Lan M, Yang X, Dong M, Chen S, Xu A, Huang S, et al. Functional variation of IL-1R-associated kinases in the conserved MyD88-TRAF6 pathway during evolution. J Immunol. 2020;204:832–43. doi:10.4049/jimmunol.1900222.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–07. doi:10.1038/nature08780.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Yamamoto Y, Sugai F, Yoshida K, Kishima Y, Sumi H, Nakamura H, Sakoda S. Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem. 2004;279(26):27320–26. doi:10.1074/jbc.M308650200.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, et al. Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244. doi:10.1200/JCO.1999.17.4.1244.
   PubMed Web of Science ®Google Scholar
• Faivre S, Santoro A, Kelley RK, Gane E, Costentin CE, Gueorguieva I, Smith C, Cleverly A, Lahn MM, Raymond E, et al. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver Int. 2019;39:1468–77. doi:10.1111/liv.14113.
   PubMed Web of Science ®Google Scholar
• Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev. 2018(10):CD012816.
   Google Scholar
• Giannelli G, Santoro A, Kelley RK, Gane E, Paradis V, Cleverly A, Smith C, Estrem ST, Man M, Wang S, et al. Correction: biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-betaRI inhibitor galunisertib. PLoS One. 2020;15:e0235580.
   PubMed Web of Science ®Google Scholar
• Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, et al. NY-ESO-1 protein Cancer vaccine with poly-ICLC and OK-432: rapid and strong induction of NY-ESO-1-specific immune responses by Poly-ICLC. J Immunother. 2017;40:140–47. doi:10.1097/CJI.0000000000000162.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Peng S, Kos F, Gravitt P, Viscidi R, Sugar E, Pardoll D, Wu TC. A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res. 2009;15:361–67. doi:10.1158/1078-0432.CCR-08-1725.
   PubMed Web of Science ®Google Scholar